Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. [electronic resource]
Producer: 20140218Description: 5867-74 p. digitalISSN:- 1550-6606
- Alemtuzumab
- Antibodies, Monoclonal, Humanized -- pharmacology
- Antigens, CD -- immunology
- Antigens, Differentiation, T-Lymphocyte -- analysis
- Antigens, Neoplasm -- immunology
- CD52 Antigen
- Cells, Cultured
- Clinical Trials, Phase III as Topic
- Glycoproteins -- immunology
- Humans
- Immunologic Memory -- drug effects
- Immunosuppressive Agents -- pharmacology
- Interferon beta-1a
- Interferon-beta -- pharmacology
- Interleukin-7 -- pharmacology
- Lymphocyte Depletion -- methods
- Lymphokines -- blood
- Lymphopenia -- blood
- Multiple Sclerosis, Relapsing-Remitting -- drug therapy
- Randomized Controlled Trials as Topic
- T-Lymphocyte Subsets -- chemistry
- Th1 Cells -- pathology
- Th17 Cells -- pathology
- Time Factors
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.